Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food-effect Bioavailability of Zemimet SR 50/1000 mg in Healthy Volunteers
NCT04070794Phase 1Unknown
- Sponsor
- LG Chem
- Start
- Nov 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of gemigliptin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by LG Chem. Primary endpoints: Peak Plasma Concentration at 48 hours, Area Under the Curve to Last Measurable Concentration at 48 hours and 1 more. Status: unknown.
02
Drugs
gemigliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04070794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04070794.